8-KLeadership ChangesMaterial AgreementsExhibits & Filings

BRISTOL MYERS SQUIBB CO 8-K Report, Material Agreement (Sep 22, 2005)

Filed September 22, 2005For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K report on September 22, 2005, detailing significant executive leadership changes and compensation adjustments. The most impactful news for investors pertains to the promotion of Lamberto Andreotti to Executive Vice President and President, Worldwide Pharmaceuticals, effective September 20, 2005. This promotion comes with a substantial compensation package, including a base salary of $975,000, target total cash compensation of $2,047,500, and a significant restricted stock award, indicating the company's strategic investment in key leadership talent. Additionally, the report discloses the planned departure of Donald J. Hayden, Jr., formerly Executive Vice President and President, Americas, effective March 2, 2006. Mr. Hayden will receive a comprehensive separation package, including severance pay, pro-rata vesting of stock and options, and eligibility for performance awards. While the executive shifts signal potential strategic realignments, the details of Mr. Hayden's exit and the compensation for Mr. Andreotti provide insights into the company's approach to leadership transitions and talent retention.

Key Highlights

  • 1Lamberto Andreotti promoted to Executive Vice President and President, Worldwide Pharmaceuticals, effective September 20, 2005.
  • 2Mr. Andreotti receives a new annual base salary of $975,000 and target total cash compensation of $2,047,500.
  • 3Mr. Andreotti is granted a restricted stock award of 125,000 shares with a three-year vesting schedule.
  • 4Elliott Sigal, M.D., Ph.D., Chief Scientific Officer, receives an increase in his target bonus and a special restricted stock award of 50,000 shares.
  • 5Donald J. Hayden, Jr., formerly Executive Vice President and President, Americas, will depart the company effective March 2, 2006.
  • 6Mr. Hayden will receive 56 weeks of base salary as severance ($746,598) and benefits related to stock and performance awards.
  • 7The report includes press releases announcing Andreotti's promotion and Hayden's planned separation as exhibits.

Frequently Asked Questions

This 8-K filing primarily informs investors about significant changes in the company's executive leadership and associated compensation. Specifically, it announces the promotion of Lamberto Andreotti to a key leadership role and the planned departure of Donald J. Hayden, Jr., along with details of their compensation and separation packages.

The promotion of Lamberto Andreotti involves a substantial increase in his compensation, including a higher base salary, increased target cash compensation, and a significant restricted stock award. This indicates the company's investment in its senior leadership and their expected contribution to future performance. Investors should note the cost associated with these executive compensation changes.

Donald J. Hayden, Jr.'s departure, though scheduled for March 2, 2006, signifies a change in leadership for the Americas region. The detailed separation agreement, including severance and benefits, suggests a structured transition. Investors may want to monitor who succeeds Mr. Hayden and what strategic direction is adopted for the Americas market following his exit.

Yes, Dr. Elliott Sigal, Chief Scientific Officer, also received an increase in his target bonus and a special restricted stock award. This suggests a broader focus on incentivizing key scientific and research leadership within the company.